0 results

    Ablynx NV

    Ablynx NV [ABLX] is focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases including inflammation, haematology, oncology and pulmonary disease.

      Related News

        SofinnovaCapital

        The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.

        SofinnovaMD Start

        The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.

        SofinnovaCrossover

        The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

        SofinnovaIndustrial Biotech

        Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.

        SofinnovaTelethon

        The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.

        SofinnovaDigital Medicine

        The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.

        SofinnovaBiovelocita

        The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.